• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thrombogenicity associated with factor IX complex concentrates.

作者信息

Lusher J M

机构信息

Children's Hospital of Michigan, Hematology/Oncology Division, Detroit 48201.

出版信息

Semin Hematol. 1991 Jul;28(3 Suppl 6):3-5.

PMID:1780767
Abstract
摘要

相似文献

1
Thrombogenicity associated with factor IX complex concentrates.与凝血因子IX复合物浓缩物相关的血栓形成性。
Semin Hematol. 1991 Jul;28(3 Suppl 6):3-5.
2
[Clinical use of factor IX concentrates].[凝血因子IX浓缩物的临床应用]
Schweiz Med Wochenschr. 1975 Sep 13;105(37):1188-90.
3
Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.凝血因子IX的血栓形成性：对凝血激活的体内影响及一例弥散性血管内凝血病例报告
Thromb Haemost. 1982 Aug 24;48(1):76-7.
4
Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.单克隆抗体纯化的凝血因子IX——与凝血酶原复合物浓缩物的血栓形成性比较
Semin Hematol. 1991 Jul;28(3 Suppl 6):15-9.
5
Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.乙型血友病患者在进行凝血因子IX替代治疗期间发生弥散性血管内凝血。
Br J Haematol. 1993 Jun;84(2):343-5. doi: 10.1111/j.1365-2141.1993.tb03078.x.
6
Current management of hemophilia B.目前B型血友病的治疗方法。
Hematol Oncol Clin North Am. 1993 Dec;7(6):1269-80.
7
Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.在手术期间及术后接受反复大剂量IX因子浓缩物治疗的B型血友病患者的高凝状态标志物。
Thromb Haemost. 1994 Jun;71(6):737-40.
8
Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.
Thromb Haemost. 1982 Dec 27;48(3):339-40.
9
Factor IX concentrates for clinical use.临床用凝血因子IX浓缩剂。
Semin Thromb Hemost. 1993;19(1):25-36. doi: 10.1055/s-2007-994003.
10
Biochemical and in vivo properties of high purity factor IX concentrates.高纯度凝血因子IX浓缩物的生化特性及体内特性
Thromb Haemost. 1993 Nov 15;70(5):768-73.

引用本文的文献

1
Association of prothrombin complexe concentrate with venous thrombosis after cardiac surgery: a case-control study.凝血酶原复合物浓缩物与心脏手术后静脉血栓形成的关联：一项病例对照研究。
Front Cardiovasc Med. 2023 Sep 15;10:1237227. doi: 10.3389/fcvm.2023.1237227. eCollection 2023.
2
Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review.预防性新鲜冰冻血浆与凝血酶原复合物浓缩剂用于肝病凝血障碍的术前管理：一项系统评价
Res Pract Thromb Haemost. 2022 May 22;6(4):e12724. doi: 10.1002/rth2.12724. eCollection 2022 May.
3
Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.
在止血算法方法中用于心血管手术后难治性出血的三因子凝血酶原复合物浓缩剂。
Vox Sang. 2019 May;114(4):374-385. doi: 10.1111/vox.12774. Epub 2019 Apr 2.
4
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.直接口服抗凝剂的药理学逆转——文献综述
Res Pract Thromb Haemost. 2018 Mar 26;2(2):251-265. doi: 10.1002/rth2.12089. eCollection 2018 Apr.
5
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.对221例接受诺艾凝（重组凝血因子IX）治疗的B型血友病患者进行血栓形成性评估。
Blood Coagul Fibrinolysis. 2018 Jan;29(1):81-86. doi: 10.1097/MBC.0000000000000681.
6
Recombinant activated factor VII in clinical practice: a 2014 update.重组活化凝血因子 VII 在临床实践中的应用：2014 年更新版
J Thromb Thrombolysis. 2015 Feb;39(2):235-40. doi: 10.1007/s11239-014-1114-1.
7
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.矛盾性血栓形成第 1 部分：因子替代疗法、遗传性凝血因子缺乏症和 APTT 延长。
J Thromb Thrombolysis. 2012 Oct;34(3):360-6. doi: 10.1007/s11239-012-0753-3.
8
Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.临床综述：凝血酶原复合物浓缩物——安全性和血栓形成性评估。
Crit Care. 2011;15(1):201. doi: 10.1186/cc9311. Epub 2011 Jan 12.
9
Warfarin reversal in anticoagulant-associated intracerebral hemorrhage.抗凝相关脑出血中的华法林逆转
Neurocrit Care. 2008;9(2):277-83. doi: 10.1007/s12028-008-9049-z.
10
Management of bleeding following major trauma: a European guideline.重大创伤后出血的管理：欧洲指南
Crit Care. 2007;11(1):R17. doi: 10.1186/cc5686.